/
GILD
$131.28-$1.45 (-1.09%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$163.0B
1,242M shares
52-week range
$108.46 – $157.29
47% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change+$62.93
Gilead Sciences Inc
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
www.gilead.com- Employees
- 17,000
- IPO / List date
- Jan 22, 1992
- HQ
- FOSTER CITY, CA
Held by traders on TradeandTell
No one on the platform currently holds GILD.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 2,152,528 | $300.0M |
| Bridgewater Associatesas of 2026-03-31 | 180,737 | $25.2M |
Insider activity (SEC Form 4)
Dividend history
TTM yield · 2.45% ($3.22/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-06-15 | $0.8200 | 2026-06-29 |
| 2026-03-13 | $0.8200 | 2026-03-30 |
| 2025-12-15 | $0.7900 | 2025-12-30 |
| 2025-09-15 | $0.7900 | 2025-09-29 |
| 2025-06-13 | $0.7900 | 2025-06-27 |
| 2025-03-14 | $0.7900 | 2025-03-28 |
| 2024-12-13 | $0.7700 | 2024-12-30 |
| 2024-09-13 | $0.7700 | 2024-09-27 |
| 2024-06-14 | $0.7700 | 2024-06-27 |
| 2024-03-14 | $0.7700 | 2024-03-28 |
Recent trades on TradeandTell
No one on the platform has traded GILD yet.
